State of Wyoming Purchases 2,251 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

State of Wyoming grew its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 103.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 4,431 shares of the specialty pharmaceutical company’s stock after buying an additional 2,251 shares during the period. State of Wyoming’s holdings in Jazz Pharmaceuticals were worth $546,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. IFP Advisors Inc bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $25,000. Quadrant Capital Group LLC lifted its position in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 101 shares during the period. CoreFirst Bank & Trust bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $28,000. Allianz SE bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $29,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 130 shares during the period. Institutional investors own 89.14% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Royal Bank of Canada reduced their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Robert W. Baird dropped their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $182.79.

Jazz Pharmaceuticals Trading Up 2.7%

JAZZ stock opened at $108.98 on Monday. The business has a fifty day moving average price of $115.73 and a 200 day moving average price of $122.09. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The stock has a market capitalization of $6.72 billion, a price-to-earnings ratio of 15.35, a P/E/G ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same period in the prior year, the business earned $2.68 earnings per share. The company’s revenue for the quarter was down .5% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. This trade represents a 10.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Seamus Mulligan acquired 100,000 shares of the firm’s stock in a transaction on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares in the company, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 28,236 shares of company stock valued at $3,956,190 in the last three months. Corporate insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.